UROGEN has announced an 18-month response period (DOR) of 80.6% from the phase environmental trial of UGN-102, a recurring, low-grade, intermediate-risk, non-muscular myologic repetitive treatment.

UROGEN has announced an 18-month response period (DOR) of 80.6% from the phase environmental trial of UGN-102, a recurring, low-grade, intermediate-risk, non-muscular myologic repetitive treatment.